共 167 条
[51]
Kim YH(2014)Prasugrel, a third-generation P2Y12 receptor antagonist, in patients with coronary artery disease undergoing elective percutaneous coronary intervention Circ J. 78 2926-86
[52]
Collet JP(2018)Effect of ticagrelor plus aspirin, ticagrelor alone, or aspirin alone on saphenous vein graft patency 1 year after coronary artery bypass grafting: A randomized clinical trial JAMA. 319 1677-40
[53]
Silvain J(2017)Ticagrelor versus clopidogrel in symptomatic peripheral artery disease N Engl J Med. 376 32-74
[54]
Barthelemy O(2019)Effects of ticagrelor versus clopidogrel in patients with coronary bifurcation lesions undergoing percutaneous coronary intervention BioMed Res Int. 2019 3170957-66
[55]
Lee CW(2016)Stopping or continuing clopidogrel 12 months after drug-eluting stent placement: the OPTIDUAL randomized trial Eur Heart J. 37 365-97
[56]
Ahn JM(2014)Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents N Engl J Med. 371 2155-30
[57]
Park DW(2014)Second-generation drug-eluting stent implantation followed by 6- versus 12-month dual antiplatelet therapy: the SECURITY randomized clinical trial J Am Coll Cardiol. 64 2086-undefined
[58]
Mauri L(2018)Safety of six-month dual antiplatelet therapy after second-generation drug-eluting stent implantation: OPTIMA-C Randomised Clinical Trial and OCT Substudy EuroIntervention 13 1923-undefined
[59]
Kereiakes DJ(undefined)undefined undefined undefined undefined-undefined
[60]
Yeh RW(undefined)undefined undefined undefined undefined-undefined